CRNX - Crinetics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue2018-12-312017-12-312016-12-31
Total Revenue2,4282,045589
Cost of Revenue24,4799,2335,100
Gross Profit-22,051-7,188-4,511
Operating Expenses
Research Development24,47924,47924,479
Selling General and Administrative6,6591,9391,533
Non Recurring---
Others---
Total Operating Expenses31,13811,1726,633
Operating Income or Loss-28,710-9,127-6,044
Income from Continuing Operations
Total Other Income/Expenses Net1,595-3025
Earnings Before Interest and Taxes-28,710-9,127-6,044
Interest Expense--8-11
Income Before Tax-27,115-9,157-6,019
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-27,115-9,157-6,019
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-27,115-9,157-6,019
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-27,115-9,157-6,019